HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $50.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 67.17% from the stock’s current price.

GMAB has been the topic of a number of other reports. Citigroup cut shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday. UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $48.50.

Genmab A/S Trading Down 2.4 %

Shares of GMAB stock opened at $29.91 on Wednesday. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.99. The company has a market capitalization of $19.76 billion, a PE ratio of 31.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.98. The firm has a fifty day simple moving average of $28.88 and a 200-day simple moving average of $31.09.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. Equities research analysts predict that Genmab A/S will post 1.09 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently made changes to their positions in GMAB. First Manhattan Co. bought a new position in shares of Genmab A/S during the 4th quarter valued at about $26,000. Headlands Technologies LLC bought a new position in shares of Genmab A/S during the 3rd quarter valued at about $27,000. Pinnacle Bancorp Inc. boosted its position in shares of Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after purchasing an additional 638 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Genmab A/S during the 3rd quarter valued at about $37,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after purchasing an additional 498 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.